Published July 9, 2025 | Version v1
Other Open

Review Protocol for "Graves' Orbitopathy following Alemtuzumab treatment for Multiple Sclerosis: a Systematic Review and Real-World Insights"

Authors/Creators

  • 1. Endocrine Unit, ASST dei Sette Laghi, Varese, Italy
  • 2. Department of Medicine and Surgery, University of Insubria, Varese, Italy
  • 3. Department of Medicine and Surgery, University of Insubria - Endocrine Unit, ASST dei Sette Laghi - Varese, Italy

Description

This file contains the full study protocol for the systematic review entitled ""Graves’ Orbitopathy following Alemtuzumab treatment for Multiple Sclerosis: a Systematic Review and Real-World Insights". 

The aim of this review is to analyse clinical, immunological, and management characteristics of Graves’ orbitopathy arising after alemtuzumab treatment in patients with multiple sclerosis. The protocol describes the research scope, eligibility and exclusion criteria, review data sources (published literature, pharmacovigilance and institutional cases database). Further, it details the approach adopted for data collection and synthesis, following PRISMA guidelines. 

Files

Review Protocol- Graves' Orbitopathy following Alemtuzumab treatment for Multiple Sclerosis.pdf

Files (176.1 kB)

Additional details

Dates

Created
2024-09-12
Protocol creation
Updated
2024-09-15
Protocol completed and updated
Submitted
2025-07-09
Protocol submission